FrancophonIA/ELRC3.0 huggingface dataset:
English: Due to the risk of partner transfer, patients hoping to achieve conception should either avoid using Senstend, or, if it is essential to achieve penetration, should wash the glans penis as thoroughly as possible 5 minutes after applying the spray but prior to intercourse (see section 4.6).
Estonian: Partnerile leviku riski tõttu peavad rasestumist soovivad patsiendid kas vältima Senstend kasutamist või kui suguühe on vajalik, pesema sugutipead nii põhjalikult kui võimalik 5 minutit pärast sprei manustamist, kuid enne seksuaalvahekorda (vt lõik 4.6).
English: Common Hypoaesthesia of male genital, erectile dysfunction, genital burning sensation
Estonian: Mehe genitaalide hüpoesteesia, erektsioonihäire, põletav aisting genitaalides
English: - The active substances are lidocaine and prilocaine.
Estonian: Mida Senstend sisaldab - Toimeained on lidokaiin ja prilokaiin.
English: Lidocaine and prilocaine are excreted in human milk, but at therapeutic doses of Senstend no effects on the breastfed newborns/infants are anticipated due to active substance transfer from the male patient to his female partner.
Estonian: Lidokaiin ja prilokaiin erituvad inimese rinnapiima, kuid Senstend terapeutiliste annuste korral ei eeldata, et toimeaine ülekandumine meespatsiendilt naispartnerile mõjutaks rinnapiimal olevaid vastsündinuid/imikuid.
English: Also contains: norflurane
Estonian: ABIAINED Sisaldab norfluraani.
English: Senstend is a combination of two medicines: lidocaine and prilocaine.
Estonian: Senstend on kahe toimeaine, lidokaiini ja prilokaiini, kombinatsioon.
English: Therefore, patients hoping to achieve conception should either avoid using Senstend, or, if this medicine is essential to achieve penetration, should wash the penis as thoroughly as possible five minutes after Senstend has been applied, but prior to intercourse.
Estonian: Seetõttu, kui patsiendid soovivad rasestuda, peavad nad kas vältima Senstend kasutamist või kui see ravim on vajalik suguühte jaoks, pesema sugutit nii põhjalikult kui võimalik viis minutit pärast Senstend aplitseerimist, kuid enne seksuaalvahekorda.
English: What Senstend is and what it is used for What you need to know before you use Senstend How to use Senstend
Estonian: Mis ravim on Senstend ja milleks seda kasutatakse Mida on vaja teada enne Senstend kasutamist Kuidas Senstend kasutada Võimalikud kõrvaltoimed Kuidas Senstend säilitada Pakendi sisu ja muu teave
English: As Senstend is applied topically to the glans penis the risk of overdose is low.
Estonian: Senstend manustamisel sugutipeale on üleannustamise risk väike.
English: The following side effects have been reported with Senstend in female partners:
Estonian: Senstend kokku puutunud naispartneritel on teatatud järgmistest kõrvaltoimetest.
English: Once the can is held upright (valve up), 1 dose of Senstend should be applied to the entire glans penis, by actuating the valve 3 times.
Estonian: Hoides mahutit püstises asendis (klapp ülespoole), aplitseeritakse 1 annus Senstend kogu sugutipeale, pihustades 3 korda.
English: Senstend is indicated for the treatment of lifelong premature ejaculation in adult men.
Estonian: Senstend on näidustatud eluaegse enneaegse ejakulatsiooni raviks täiskasvanud meestel.
English: Holding the can upright (valve up), apply 1 dose (3 sprays) of Senstend to the entire head of the penis, by covering one third with each spray.
Estonian: Hoidke mahutit püstises asendis (klapp ülespoole), aplitseerige 1 annus (3 pihustust) Senstend kogu sugutipeale, kattes ühe kolmandiku iga pihustusega.
English: Deterioriation was observed when Senstend was used with polyurethane-based female and male condoms.
Estonian: Senstend kasutamisel koos polüuretaanipõhiste naiste ja meeste kondoomidega täheldati degradeerumist.
English: Patients hoping to achieve conception should either avoid using Senstend, or, if it is essential to achieve penetration, should wash the glans penis as thoroughly as possible prior to intercourse.
Estonian: Rasestumist soovivad patsiendid peavad kas vältima Senstend kasutamist või kui suguühe on vajalik, pesema sugutipead enne seksuaalvahekorda nii põhjalikult kui võimalik.
English: Senstend 150 mg/ml + 50 mg/ml cutaneous spray, solution lidocaine/prilocaine
Estonian: Senstend 150 mg/ml + 50 mg/ml nahasprei, lahus lidokaiin/prilokaiin
English: Senstend is indicated for the treatment of primary premature ejaculation in adult men.
Estonian: Senstend on näidustatud esmase enneaegse ejakulatsiooni raviks täiskasvanud meestel.
English: As this medicine is applied to the surface of the head of the penis the risk of overdose is low.
Estonian: Kui te kasutate Senstend rohkem kui ette nähtud Kuivõrd seda ravimit kantakse sugutipea pinnale, on üleannustamise risk väike.
English: Senstend is a colourless to light yellow cutaneous spray, solution in an aluminium spray container with metering valve.
Estonian: Kuidas Senstend välja näeb ja pakendi sisu Senstend on värvitu kuni helekollane nahasprei lahus alumiiniumist spreimahutis koos mõõteklapiga.
English: A higher rate of erectile dysfunction and male genital hypoaesthesia may be experienced when using Senstend with male condoms.
Estonian: Senstend kasutamisel koos meeste kondoomidega on võimalik erektsioonihäirete ja mehe genitaalide hüpoesteesia esinemissageduse suurenemine.
English: During the 3 months of the double-blind treatment phase, the geometric mean IELT increased from 0.58 to 3.17 minutes in the Senstend group and from 0.56 to 0.94 minutes in the placebo group.
Estonian: Senstend efektiivsuse hindamiseks enneaegse ejakulatsiooni ravis mõõdeti IELT-d ning ejakulatsioonikontrolli, seksuaalse rahulduse ja stressi kaastulemusnäitajaid, kasutades selleks IPE-d. 3-kuulise topeltpimeda ravifaasi ajal suurenes IELT geomeetriline keskmine 0,58 minutilt 3,17 minutini Senstend rühmas ja 0,56 minutilt 0,94 minutini platseeborühmas.
English: Plasma levels of these metabolites detected after administration of Senstend in clinical trials were low in both male and female subjects, even after doses of it many times in excess of the clinical dose were applied.
Estonian: Isegi pärast kliinilisi annuseid mitmeid kordi ületavate Senstend annuste manustamist oli kliinilistes uuringutes nende metaboliitide plasmasisaldus madal nii mees- kui ka naissoost osalejatel.
English: Patients with severe hepatic disease, because of their inability to metabolise local anaesthetics normally, are at greater risk of developing toxic plasma concentrations of lidocaine and prilocaine (see section 4.2).
Estonian: Nende võimetuse tõttu normaalselt lokaalanesteetikume metaboliseerida esineb raske maksahaigusega patsientidel suurem lidokaiini ja prilokaiini toksiliste plasmakontsentratsioonide tekkerisk (vt lõik
English: Senstend is only indicated for application to the glans penis.
Estonian: Senstend on näidustatud ainult aplitseerimiseks sugutipeale.
English: Medicinal products subject to medical prescription
Estonian: RAVIMI VÄLJASTAMISTINGIMUSED
English: Common Vulvovaginal burning sensation, hypoaesthesia Uncommon Vulvovaginal discomfort, vaginal pain,
Estonian: Vulvovaginaalne ebamugavustunne, vaginaalne valu, vulvovaginaalne sügelus
English: There is no relevant use of Senstend in the paediatric population for the indication of treatment of primary premature ejaculation in adult men.
Estonian: Senstend ei kasutata lastel, sest selle näidustus on esmase enneaegse ejakulatsiooni ravi täiskasvanud meestel.
English: vulvovaginal pruritus
Estonian: Vulvovaginaalne kipitustunne, hüpoesteesia
English: Senstend provides topical anaesthesia to the glans penis.
Estonian: Senstend toimib sugutipea toopilise anesteetikumina.
English: Package leaflet: Information for the user Senstend 150 mg/ml + 50 mg/ml cutaneous spray, solution lidocaine/prilocaine
Estonian: RAVIMPREPARAADI NIMETUS Senstend 150 mg/ml + 50 mg/ml nahasprei, lahus lidokaiin/prilokaiin
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Estonian: B. HANKE- JA KASUTAMISTINGIMUSED VÕI PIIRANGUD Retseptiravim.
English: The following side effects have been reported with Senstend in male patients:
Estonian: Senstend kasutavatel meespatsientidel on teatatud järgmistest kõrvaltoimetest.
English: Senstend 150 mg/ml + 50 mg/ml cutaneous spray, solution
Estonian: RAVIMPREPARAADI NIMETUS Senstend 150 mg/ml + 50 mg/ml nahasprei, lahus
English: senstend
Estonian: Nahaärritus
English: Cutaneous spray, solution 6.5 ml
Estonian: 6,5 ml
English: Plethora Pharma Solutions Ltd. Puh/Tel: +44 (0)20 3077 5400
Estonian: Suomi/Finland Plethora Pharma Solutions Ltd. Puh/Tel: +44 (0)20 3077 5400
English: Plethora Pharma Solutions Ltd. Tél/Tel: +44 (0)20 3077 5400
Estonian: Luxembourg/Luxemburg Plethora Pharma Solutions Ltd. Tél/Tel: +44 (0)20 3077 5400
English: • Feeling light-headed or dizzy
Estonian: • peapööritus või pearinglus;
English: The recommended dose is 2 inhalations twice a day.
Estonian: Soovitatav annus on 2 inhalatsiooni kaks korda ööpäevas.
English: The combination has been shown to be effective at improving patients' lung function, with both components contributing to this effect.
Estonian: Nende kombinatsioon on tõendatult efektiivne patsientide kopsufunktsiooni parandamisel ning kumbki komponent soodustab seda toimet.
English: Further information on Bevespi Aerosphere can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Bevespi-Aerosphere.
Estonian: Lisateave ravimi Bevespi Aerosphere kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Bevespi-Aerosphere.
English: The European Medicines Agency therefore decided that Bevespi Aerosphere's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et ravimi Bevespi Aerosphere kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Bevespi Aerosphere (glycopyrronium bromide / formoterol) EMA/752588/2018
Estonian: Bevespi Aerosphere (glükopürrooniumbromiid) EMA/752588/2018
English: Patients who received placebo (a dummy treatment), on the other hand, had increases of up to 8 ml or reductions of up to 20 ml.
Estonian: Samas esines platseebot (näiv ravim) saanud patsientidel mahu suurenemist kuni 8 ml või vähenemist kuni 20 ml võrra.
English: What measures are being taken to ensure the safe and effective use of Bevespi Aerosphere?
Estonian: Mis meetmed võetakse, et tagada ravimi Bevespi Aerosphere ohutu ja efektiivne kasutamine?
English: The most common side effects with Bevespi Aerosphere (which may affect up to 1 in 10 people) include headache, nausea (feeling sick), muscle spasms and dizziness.
Estonian: Bevespi Aerosphere kõige sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on peavalu, iiveldus, lihasspasmid ja peapööritus.
English: It contains the active substances glycopyrronium bromide and formoterol.
Estonian: Ravim sisaldab toimeainena glükopürrooniumbromiidi ja formoterooli.
English: Patients should be shown how to use the inhaler correctly by a doctor or other healthcare professional.
Estonian: Arst või muu tervishoiutöötaja peab patsiendile näitama, kuidas kasutada inhalaatorit õigesti.
English: Side effects reported with Bevespi Aerosphere are carefully evaluated and any necessary action taken to protect patients.
Estonian: Ravimi Bevespi Aerosphere kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: As for all medicines, data on the use of Bevespi Aerosphere are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse ravimi Bevespi Aerosphere kasutamise kohta pidevat järelevalvet.
English: For more information about using Bevespi Aerosphere, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet ravimi Bevespi Aerosphere kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Three main studies in over 5,000 patients with COPD have shown that Bevespi Aerosphere is effective at improving patients' FEV1 (the maximum volume of air they can breathe out in one second).
Estonian: Kolmes põhiuuringus, milles osales üle 5000 kroonilise obstruktiivse kopsuhaigusega patsiendi, tõendati, et Bevespi Aerosphere on efektiivne patsientide FEV1 (esimese sekundi jooksul väljahingatava õhu maksimaalne maht) suurendamisel.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bevespi Aerosphere have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Bevespi Aerosphere ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs.
Estonian: See tähendab, et see blokeerib kopsus lihasrakkude muskariiniretseptorid (toime sihtmärk).
English: When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open.
Estonian: Seondudes retseptoritega põhjustab see lihaste lõdvestumist, mis hoiab hingamisteed avatuna.
English: Bevespi Aerosphere (glycopyrronium bromide / formoterol)
Estonian: Bevespi Aerosphere (glükopürrooniumbromiid)
English: What is Bevespi Aerosphere and what is it used for?
Estonian: Mis on Bevespi Aerosphere ja milleks seda kasutatakse?
English: In these studies, patients treated with Bevespi Aerosphere for 24 weeks had FEV1 increases of around 135 to 150 ml.
Estonian: Nendes uuringutes suurenes ravimiga Bevespi Aerosphere ravitud patsientidel FEV1 ligikaudu 135150 ml võrra.
English: Other information about Bevespi Aerosphere
Estonian: Muu teave ravimi Bevespi Aerosphere kohta
English: The studies also showed that Bevespi Aerosphere improved FEV1 more than the single components in the medicine.
Estonian: Uuringutes tõendati ka, et Bevespi Aerosphere suurendas FEV1 rohkem kui ravimi kumbki toimeaine eraldi.
English: Bevespi Aerosphere is used for maintenance (regular) treatment.
Estonian: Ravimit Bevespi Aerosphere kasutatakse säilitusraviks (tavaliseks raviks).
English: Bevespi Aerosphere is a medicine used in adults to relieve the symptoms of chronic obstructive pulmonary disease (COPD).
Estonian: Bevespi Aerosphere on ravim, mida kasutatakse kroonilise obstruktiivse kopsuhaiguse sümptomite leevendamiseks täiskasvanutel.
English: Glycopyrronium bromide is a muscarinic receptor antagonist.
Estonian: Glükopürrooniumbromiid on muskariiniretseptori antagonist.
English: Side effects are considered mild to moderate in severity and are similar to other COPD medicines.
Estonian: Kõrvalnähte peetakse kergeks kuni mõõdukaks ning need on sarnased kroonilise obstruktiivse kopsuhaiguse muude ravimite kõrvalnähtudega.
English: For the full list of side effects and restrictions of Bevespi Aerosphere, see the package leaflet.
Estonian: Ravimi Bevespi Aerosphere kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Finally, the studies showed that Bevespi Aerosphere can lead to modest improvements in symptoms such as breathlessness.
Estonian: Samuti tõendasid uuringud, et Bevespi Aerosphere võib vähesel määral leevendada sümptomeid, nt õhupuudustunnet.
English: The medicine has also shown some effect on symptoms such as breathlessness although this appears modest.
Estonian: Samuti leevendab ravim tõendatult mõneti, kuigi vähe sümptomeid (nt õhupuudustunne).
English: What are the risks associated with Bevespi Aerosphere?
Estonian: Mis riskid ravimiga Bevespi Aerosphere kaasnevad?
English: Bevespi Aerosphere is available as a liquid in a portable inhaler device.
Estonian: Ravimit Bevespi Aerosphere turustatakse vedelikuna kaasaskantavas inhalaatoris.
English: An overview of Bevespi Aerosphere and why it is authorised in the EU
Estonian: Ülevaade ravimist Bevespi Aerosphere ja ELis müügiloa väljastamise põhjendus
English: How is Bevespi Aerosphere used?
Estonian: Kuidas ravimit Bevespi Aerosphere kasutatakse?
English: Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open.
Estonian: Glükopürrooniumbromiidi sissehingamisel lõdvestuvad hingamisteede lihased, mis aitab hoida hingamisteed avatuna.
English: The two active substances in Bevespi Aerosphere work in different ways to widen the airways and improve breathing in COPD.
Estonian: Bevespi Aerosphere sisaldab kahte toimeainet, millel on erinevad hingamisteede laiendamise ja kroonilise obstruktiivse kopsuhaigusega patsientide hingamisfunktsiooni parandamise mehhanismid.
English: What benefits of Bevespi Aerosphere have been shown in studies?
Estonian: Milles seisneb uuringute põhjal ravimi Bevespi Aerosphere kasulikkus?
English: The components in Bevespi Aerosphere are well established treatments of COPD.
Estonian: Ravimi Bevespi Aerosphere toimeained on kroonilise obstruktiivse kopsuhaiguse hästi teada ravimid.
English: How does Bevespi Aerosphere work?
Estonian: Kuidas Bevespi Aerosphere toimib?
English: It is also part of Chinese traditional medicine.
Estonian: See on samuti traditsioonilise Hiina meditsiini osa.
English: They are generally taken three to four times a day and they should be taken for not more than 1-2 weeks.
Estonian: Üldiselt manustatakse ravimit kolm kuni neli korda päevas kuni 1-2 nädala jooksul.
English: This information should always be read carefully before using a product.
Estonian: Enne toote kasutamist peab seda teavet alati tähelepanelikult lugema.
English: Many traditional herbal medicines have not been fully investigated with current scientific methods.
Estonian: Paljusid traditsioonilisi taimseid ravimeid ei ole nüüdisaegsete teaduslike meetoditega täielikult uuritud.
English: This image is not intended to encourage collection from the wild.
Estonian: Pildi eesmärk ei ole soodustada loodusest taime korjamist.
English: This traditional use must cover a period of at least 30 years with 15 years of this use within the Community.
Estonian: Traditsioonilise kasutuse kestuseks loetakse vähemalt 30-aastast kasutust, millest 15 aastat on olnud ühendusesisene.
English: Sweet fennel is a plant that grows wild in most parts of temperate Europe, but is generally considered indigenous to the shores of the Mediterranean from where it spreads eastwards to India.
Estonian: Magus apteegitill on taim, mis kasvab looduslikult peaaegu kõikjal parasvöötme Euroopas; päritolukohaks peetakse üldiselt Vahemere rannikut, sealt on taim levinud itta Indiasse.
English: vulgare var. dulce (Miller) Thellung is provided in the HMPC Assessment Report, overview of comments received during the public consultation period and other related documents which can be found here.
Estonian: vulgare var. dulce (Miller) Thellung, on taimsete ravimite komitee hindamisaruandes, avaliku konsulteerimisperioodi jooksul saadud märkuste ülevaates ja muudes seotud dokumentides siin.
English: The long-standing use over more than 30 years and limited experimental studies make the traditional use in the above-mentioned indications plausible.
Estonian: Pikaajaline üle 30-aastane kasutus ja mõni katseuuring kinnitavad traditsioonilise kasutuse otstarbekohasust eespool mainitud näidustustel.
English: IMPORTANT NOTE: The image is provided to give additional information on the source of the herbal substance/preparation.
Estonian: TÄHTIS MÄRKUS: Lisateabena on taimse aine / valmistise taimest pilt.
English: The EU pharmaceutical legislation provides an opportunity for traditional herbal medicines to be officially registered, based on their traditional use, if they can be used safely without the support from a medical doctor for diagnosis, treatment and follow-up.
Estonian: Euroopa Liidu farmaatsiaõigusaktid sätestavad võimaluse traditsiooniliste taimsete ravimite ametlikuks registreerimiseks, mis põhineb nende traditsioonilisel ja ohutul kasutusel ilma arsti diagnoosi, ravi ja järelkontrollita.
English: The botanical Latin name of the plant is Foeniculum vulgare Miller subsp.
Estonian: Taime botaaniline ladinakeelne nimetus on Foeniculum vulgare Miller subsp.
English: Sweet fennel fruit medicines are generally well tolerated.
Estonian: Magusa apteegitilli vilja ravimeid talutakse üldiselt hästi.
English: Sweet fennel fruit medicines are not recommended for use in children under 4 years of age because there is not enough information on their safe use in this group.
Estonian: Ravimit ei ole soovitatav kasutada alla 4-aastastel lastel, sest ravimi kasutamise ohutuse kohta selles vanusegrupis pole piisavalt teavet.
English: Sweet fennel fruit medicines should not be used in people who may be hypersensitive (allergic) to sweet fennel.
Estonian: Magusa apteegitilli vilja ravimeid ei tohi kasutada patsiendid, kes võivad olla magusa apteegitilli suhtes ülitundlikud (allergilised).
English: There are few studies looking at the safety of sweet fennel fruit preparations, but the many years of experience of their use in man indicate that they are sufficiently safe.
Estonian: Magusa apteegitilli vilja valmististe ohutuse uuringuid on vähe, kuid aastatepikkune kasutuskogemus inimestel näitab nende piisavat ohutust.
English: Because there have been no tests looking at the effects of sweet fennel fruit medicines during pregnancy or lactation, they should not be used in women who are pregnant or breast-feeding as a general precaution.
Estonian: Et magusa apteegitilli vilja ravimite toimet raseduse ega imetamise ajal ei ole uuritud, ei tohi ravimit üldise ettevaatusmeetmena raseduse ega imetamise ajal kasutada.
English: VULGARE VAR. DULCE (MILLER) THELLUNG, FRUCTUS FENNEL FRUIT, SWEET HMPC Assessment Report Summary for the Public
Estonian: VULGARE VAR. DULCE (MILLER) THELLUNG, FRUCTUS MAGUSA APTEEGITILLI VILI Taimsete ravimite komitee hindamisaruande kokkuvõte üldsusele
English: The justification for the use of these preparations is found in their traditional use as herbal medicines.
Estonian: Nende valmististe kasutamise põhjenduseks on traditsiooniline kasutamine taimse ravimina.
English: Clinical trials on sweet fennel fruit medicines are limited, but pharmacological data support the plausibility of the traditional medicinal use.
Estonian: Ravimite kliinilised uuringud on piiratud, kuid farmakoloogilised andmed toetavad traditsioonilises meditsiinis kasutamise otstarbekohasust.
English: Sweet fennel fruit medicines can be used from the age of 4 years.
Estonian: Magusa apteegitilli vilja ravimeid võib kasutada vähemalt 4-aastastel lastel.
English: Other information about sweet fennel fruit medicines The medicinal use of sweet fennel fruit is part of traditional European Phytotherapy.
Estonian: Muu teave magusa apteegitilli vilja ravimite kohta Magusa apteegitilli vilja meditsiiniline kasutus on Euroopa taimeteraapia traditsiooni osa.
English: Community list entries are authorised by the European Commission further to the scientific opinion of the HMPC and describe the herbal medicines, including their content, how they are used, what they are used for, how they work and how they can be used safely.
Estonian: Pärast taimsete ravimite komitee teaduslikku arvamuse hindamist kinnitab Euroopa Komisjon kanded ühenduse loetellu; kannetes kirjeldatakse taimseid ravimeid, sealhulgas nende koostist, manustamisviisi, näidustusi, toimet ja ohutut kasutamist.
English: Furthermore, the secretolytic and expectorant effect of two main components of sweet fennel fruit (anethole and estragole) observed in a study conducted in rabbits, could also support the plausibility of the traditional use of fennel in cough associated with colds.
Estonian: Lisaks toetab magusa apteegitilli vilja kahe peamise komponendi (anetool ja estragool) sekretolüütiline ja röga väljutav toime, mida täheldati küülikute uuringus, apteegitilli kasutamist külmetusest põhjustatud köha korral.
English: Many components have been identified in preparations containing sweet fennel fruit and it is not possible to define precisely the action of each component.
Estonian: Magusa apteegitilli vilja sisaldavates valmististes on mitmeid komponente, mille täpset toimet ei ole eraldi võimalik määratleda.